



Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

Prof. Yong Poovorawan
Center of Excellence in Clinical Virology
Faculty of Medicine Chulalongkorn University

**The mode of transmission of
HBV in SE is perinatal
transmission**



Therefore, immature of immunity in children are **not** effect to protective from HBV infection

In 1992, WHO



has recommended HB vaccine in immunization programs to infants for all countries by the year 1997.

In the year 1986

We started pregnant women screening

HBsAg positive 6%

HBeAg positive 40% of HBsAg



**Neonates born from HBV carrier mothers
were immunized with HB vaccine**



Protective efficacy of hepatitis B vaccine without immunoglobulin in high-risk neonates

NCBI Resources How To

PubMed
US National Library of Medicine
National Institutes of Health

PubMed Limits Advanced

Display Settings: Abstract

JAMA. 1989 Jun 9;261(22):3278-81.

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers.

Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A.
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and Hospital, Bangkok, Thailand.

Abstract


We have assessed the protective efficacy of a recombinant DNA hepatitis B vaccine alone in infants of women who were positive for the surface antigen at additional doses 1, 2, and 12 months later. No significant adverse reactions to vaccination were observed and the vaccine was highly immunogenic. Only evidenced by the persistent presence of hepatitis B surface antigen in serum samples. Without immunoprophylaxis, 65% to 90% of such infants would be hepatitis B immunoglobulin, therefore, considerably decreased the incidence of the carrier state.

PMID: 2523981 [PubMed - indexed for MEDLINE]

+ MeSH Terms, Substances

+ LinkOut - more resources


JAMA
The Journal of the American Medical Association
September 3, 1992



Poovorawan Y, et al, 1989



High Protective Efficacy in Neonates with or without HBIg



Hepatitis B immunization programme in Thailand

**August 1988 : Demonstrate methods
of incorporating HB vaccine
into EPI program**

Program sites : 2 provinces




- Chiangmai**
- Chonburi**

Thailand EPI

- At birth **HB1**, BCG
- 2 months OPV1, DPT1, **HB2**
- 4 months OPV2, DPT2
- 6 months OPV3, DPT3, **HB3**
- 9-12 months Measles or MMR
- 18 Months OPV4, DPT4,
JE1 & 2
(2 weeks apart, booster 1 yr after)
- 4-6 years OPV5, DPT5, Measles

Universal HB vaccination in Thailand

- 1988 implemented in 2 provinces
- 1990 included in 10 more provinces
- 1992 all newborns







Long term study of DTP-HB in Thai children





Center of Excellence in Clinical Virology



Combine HBV-DTP vaccine was started in 1994




The schedule for HB vaccine


Birth	BCG	HB vac
2 mos		OPV, DTPw- HB
4 mos		OPV, DTPw- HB
6 mos		OPV, DTPw- HB
9-12 mos		MMR1
18 mos		OPV, DTPw (JE vac 0, 1, 6-12)
4-6 yrs		OPV, DTPw, MMR2

Sero survey of HBV markers in ChaingRai province, 2004


**Seroprevalence of HBsAg in
ChaingRai 2004**



**Seroprevalence of anti-HBs in
ChaingRai 2004**



**Seroprevalence of anti-HBc
ChaingRai 2004**




Effect of dose number and interval between the first two doses of hepatitis B vaccine on the carrier rate of infants born to hepatitis B surface antigen positive mothers



Prof. Yong Poovorawan, MD

Center of Excellence in Clinical Virology Faculty of Medicine Chulalongkorn University



(A) Location of Chiangrai, the northern most province of Thailand

(B) 11 district hospitals participating in this study

The number in B stands for 1 - Khun Tan; 2 – Thoeng; 3 - Wiang Kaen; 4 - Phan;

5 - Chiang Saen; 6 - Wiang Pa Pao; 7 - Phaya Mengrai; 8 - Mae Sai; 9 - Mae Chan;

10 - Mae Fa Luang and 11 - Mueang Chiangrai districts.

Recommended HB vaccination schedule for newborns of HBsAg positive and negative mothers, Chiangrai, 2004 - 2006

Group	Age					
	Birth	1 month	6 weeks	2 months	4 months	6 months
Children born from HBsAg negative mother	HB			DTPw-HB	DTPw - HB	DTPw - HB
Children born from HBsAg positive mother						
- Group 1	HB	HB		DTPw-HB	DTPw - HB	DTPw - HB
- Group 2	HB		DTPw- HB		DTPw - HB	DTPw - HB

HBV carrier rate by HB1-2 interval in the study

Interval	Total children	No of HB carrier	HB carrier rate (%) and 95%CI
Group 1	277	4	1.44 , 0.46 - 3.91
Group 2	240	11	4.58, 2.43 - 8.28
By HB1-2 interval			
• Less than 6 weeks	21	1	4.76, 0.25-25.87
• 6 – 7 weeks	30	1	3.33, 0.17-19.05
• 8 – 9 weeks	89	2	2.25, 0.39-8.65
• 10 weeks above	100	7	7.00, 3.1-14.38

Thailand EPI


since 2009

Birth	BCG HB vac
1 mo	(HBsAg+ve mother) HB vac
2 mos	OPV, DTPw-HB
4 mos	OPV, DTPw-HB
6 mos	OPV, DTPw-HB
9-12 mos	MMR1
18 mos	OPV, DTPw (JE vac 0, 1, 6-12)
4-6 yrs	OPV, DTPw, MMR2


1994-1998




2005




2006



2007




2008



**Combine DTPw-HB
vaccine into
Thailand EPI
program**

**Study of the Impact of
universal HB immunization
as part of EPI program
(2014)**

Impact of universal HB vaccination in Thailand since 1992




Impact of universal HB vaccination in Thailand since 1992

anti-HBs

Seroprotective
(≥ 10 mIU/mL)
(%)


(n = 5954)



Impact of universal HB vaccination in Thailand since 1992

anti-HBc +ve
(%)


(n = 5964)



Conclusion

By the year 2030

We hope that HBV will be eliminated by universal HB vaccine into newborn and effective HBV therapy



Acknowledgement

